United Therapeutics Corporation

Equities

UTHR

US91307C1027

Market Closed - Nasdaq Other stock markets 16:00:00 2025-07-08 EDT			5-day change	1st Jan Change
294.42 ^USD	+1.39%		+2.46%	-16.56%

06-30	United Therapeutics' Tyvaso to Benefit from Q2 Seasonality, UBS Says	MT
06-30	UBS Adjusts Price Target on United Therapeutics to $385 From $410, Maintains Buy Rating	MT

United Therapeutics Corporation, Q1 2025 Earnings Call, Apr 30, 2025

Published on 2025-04-30 at 07:00, updated on 2025-04-30 at 09:00

Presentation Operator Message
Operator (Operator)

Good morning, and welcome to the United Therapeutics Corporation First Quarter 2025 Corporate Update. My name is Dorwin, and I will be your conference

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about United Therapeutics Corporation

United Therapeutics' Tyvaso to Benefit from Q2 Seasonality, UBS Says	06-30	MT
UBS Adjusts Price Target on United Therapeutics to $385 From $410, Maintains Buy Rating	06-30	MT
United Therapeutics Corporation and Intermountain Health Announce the First Patient Treated with External Liver Support Using a Bioengineered Liver	06-24	CI
Liquidia Gets $50 Million From Healthcare Royalty	06-23	MT
United Therapeutics Corporation Concludes Enrollment of the Advance Outcomes Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension	06-23	CI
United Therapeutics delivers 18th consecutive quarter of topline growth	06-17
United Therapeutics Insider Sold Shares Worth $3,079,514, According to a Recent SEC Filing	06-16	MT
Insmed Shares Rise After Phase 2b Trial of Treprostinil Inhalation Powder in PAH Meets Endpoints	06-10	MT
Insmed's drug for rare lung disease achieves 'home run' in mid-stage trial	06-10	RE
Liquidia, United Therapeutics Shares Fall Pre-Bell After Rival Insmed's Phase 2b PAH Trial Meets Endpoints	06-10	MT
Liquidia Set to Make First Commercial Shipment of Yutrepia for Pulmonary Hypertension	06-02	MT
Cantor Fitzgerald Initiates United Therapeutics at Overweight With $405 Price Target	06-02	MT
Liquidia Receives FDA Approval on Yutrepia for Treatment of Pulmonary Hypertension	05-23	MT
Liquidia Faces Patent Litigation Filed by United Therapeutics	05-12	MT
Liquidia Says New Litigation Filed Against Co In U.S.	05-12	RE
United Therapeutics Corporation, Q1 2025 Earnings Call, Apr 30, 2025	04-30
United Therapeutics Q1 Earnings, Revenue Rise	04-30	MT
Earnings Flash (UTHR) United Therapeutics Posts Q1 Revenue $794.4M, vs. FactSet Est of $729.3M	04-30	MT
United Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025	04-30	CI
United Therapeutics Enters Credit Agreement With Wells Fargo - SEC Filing	04-28	RE
United Therapeutics Corporation Announces Credit Agreement Established for A $2.5 Billion Revolving Facility	04-28	CI
Liquidia Corp Unit Files Patent Infringement Action Against United Therapeutics	04-22	RE
BofA Securities Upgrades United Therapeutics to Neutral From Underperform	04-21	MT
United Therapeutics Insider Sold Shares Worth $3,121,543, According to a Recent SEC Filing	04-21	MT
United Therapeutics Insider Sold Shares Worth $1,138,200, According to a Recent SEC Filing	04-08	MT